UP!

FLXN $9.12

FLXN target price
9.12
0
0
Flexion Therapeutics, Inc.
Type
Public
Traded as NASDAQ: FLXN
Industry Pharmaceuticals
Headquarters Burlington, MA
Website Flexion Therapeutics

Flexion Therapeutics is an American pharmaceutical company based in Burlington, Massachusetts that is developing reformulated sustained release versions of existing drugs that are intended to be injected into the joint to treat osteoarthritis.

It was founded around 2007 by two former Eli Lilly & Co. executives and went public in 2014.

In November 2016 the FDA accepted Flexion's New Drug Application for FX006, a sustained-release formulation of triamcinolone acetonide (a corticosteroid), branded "Zilretta". In March 2017 FiercePharma reported that Flexion was in discussions with Sanofi about a possible acquisition, valued at the time at around $1 billion.

Flexion had been developing FX007, a selective small-molecule TrkA inhibitor that it had licensed from AstraZeneca, for osteoarthritis. As of March 2017 Flexion had terminated development. Flexion had also terminated development of FX005, a P38 mitogen-activated protein kinase inhibitor, by that time.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2021 2022-03-08 Future report Set alerts
Q3 2021 2021-11-12 -0.60 -0.60
Q2 2021 2021-08-04 -0.44 -0.44
Q1 2021 2021-05-12 -0.57 -0.57
Q4 2020 2021-03-10 -0.37 -0.37
Q3 2020 2020-11-04 -0.50 0.00
Q2 2020 2020-08-05 -0.76 -0.76
Q1 2020 2020-05-07 -0.95 -0.95
Q4 2019 2020-03-12 -0.88 -0.88
Q3 2019 2019-11-07 -1.00 -1.00

Ratings

2016-07-01 Reiterated Rating Janney Montgomery Scott Buy $30.00
2016-06-30 Reiterated Rating RBC Capital Buy
2016-06-30 Reiterated Rating Wells Fargo Buy
2016-06-30 Reiterated Rating Royal Bank Of Canada Buy
2016-06-30 Reiterated Rating Wells Fargo & Co. Buy
2016-06-28 Initiated Coverage BMO Capital Markets Outperform $35.00
2016-05-27 Reiterated Rating Janney Montgomery Scott Buy $30.00
2016-05-27 Reiterated Rating Needham & Company LLC Buy $28.00 to $34.00
2016-05-26 Reiterated Rating Cantor Fitzgerald Buy
2016-05-14 Reiterated Rating Cantor Fitzgerald Buy
2016-05-03 Initiated Coverage Wells Fargo Outperform
2016-04-29 Reiterated Rating Cantor Fitzgerald Buy $44.00
2016-04-05 Reiterated Rating Cantor Fitzgerald Buy $44.00
2016-04-04 Reiterated Rating Needham & Company LLC Buy $28.00
2016-03-11 Reiterated Rating Cantor Fitzgerald Buy $44.00
2016-02-17 Reiterated Rating Janney Montgomery Scott Buy $27.00 to $33.00
2016-02-17 Reiterated Rating RBC Capital Outperform $44.00
2016-01-13 Reiterated Rating Cantor Fitzgerald Buy $44.00
2015-12-13 Reiterated Rating RBC Capital Outperform $44.00
2015-12-10 Initiated Coverage Janney Montgomery Scott Buy $27.00
2015-12-02 Reiterated Rating Cantor Fitzgerald Buy $44.00
2015-11-04 Initiated Coverage Cantor Fitzgerald Buy $44.00
2015-09-09 Reiterated Rating RBC Capital Buy
2015-09-09 Lower Price Target Needham & Company LLC Buy $31.00 to $28.00
2015-09-02 Reiterated Rating Northland Securities Buy $40.00
2015-08-07 Boost Price Target Janney Montgomery Scott Buy $34.50 to $39.50
2015-07-31 Boost Price Target RBC Capital Outperform $41.00 to $44.00
2015-05-23 Reiterated Rating BMO Capital Markets Outperform $36.00 to $38.00
2015-05-14 Initiated Coverage Northland Securities Outperform $40.00
2015-03-30 Initiated Coverage MLV & Co. Buy $38.00
2015-03-24 Boost Price Target Janney Montgomery Scott Buy $30.00 to $34.50
2015-02-16 Initiated Coverage RBC Capital Outperform $37.00
2014-11-26 Reiterated Rating Summer Street Buy
2014-09-10 Boost Price Target Needham & Company LLC $26.00 to $31.00
2014-09-10 Boost Price Target BMO Capital Markets $33.00 to $36.00
2014-08-14 Initiated Summer Street Research Buy $25
2014-08-14 Initiated Coverage Summer Street Buy $25.00
2014-03-19 Initiated Coverage Janney Montgomery Scott Buy $25.00
2014-03-10 Initiated Coverage Wells Fargo & Co. Outperform
2014-03-10 Initiated Coverage BMO Capital Markets Outperform $33.00
2014-03-10 Initiated Coverage Needham & Company LLC Buy $26.00
2014-03-10 Initiated Coverage Wells Fargo Outperform
2016-07-01 Reiterated Rating Janney Montgomery Scott Buy $30.00
2016-06-30 Reiterated Rating RBC Capital Buy
2016-06-30 Reiterated Rating Wells Fargo Buy
2016-06-30 Reiterated Rating Royal Bank Of Canada Buy
2016-06-30 Reiterated Rating Wells Fargo & Co. Buy

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
Bolzon Bradley J PhD 20.52%  (3206807) FLXN /
Novo A/S SEE REMARKS 13.65%  (2133131) AKBA / ALDR / CRVS / FLXN / INGN / LPTN / OPHT / OTIC / RETA / RGDO / ZSPH /
Tordjman Rafael 13.48%  (2105491) FLXN /
Sofinnova Partners SAS 13.41%  (2095491) FLXN /
PFIZER INC 10.80%  (1687250) AQXP / CLDN / FLXN /
Schwab Andrew J. 9.68%  (1512076) FLXN /
5AM Ventures II LP 9.68%  (1512076) FLXN /
Bodick Neil Chief Medical Officer 0.48%  (74605) FLXN /
Clayman Michael D. President and CEO 0.41%  (64728) AKBA / FLXN /
LUBASH BARBARA N 0.13%  (20739) FLXN /
Versant Ventures III, LLC 0.13%  (20739) FLXN / VCYT /
KELLEY SCOTT Chief Medical Officer 0.10%  (14892) FLXN /
Wentworth Kerry Chief Regulatory Officer 0.08%  (12307) AGEN / FLXN /
Deniz Yamo Chief Medical Officer 0.06%  (9000) FLXN /
Levine Mark S. SVP & General Counsel 0.05%  (8333) FLXN / NERV /
DRISCOLL FREDERICK W Chief Financial Officer 0.05%  (7777) FLXN / MEIP / NVAX / OXGN /
COLELLA SAMUEL D 0.03%  (5000) ALXA / FLDM / FLXN / GHDX / VCYT /
Versant Venture Capital III, L.P. 0.01%  (2250) FLXN / IMDZ /
MERRIFIELD C ANN 0.01%  (2000) CBRX / FLXN /
Stejbach Mark 0.01%  (1580) ALKS / FLXN / TNGN /